Beyond Probiotics: A Clinically Validated, Pasteurized Akkermansia muciniphila Postbiotic for Muscle Health

The Market Opportunity: Muscle Health in an Aging World

Populations are aging, and with age comes a progressive decline in muscle health — encompassing the loss of strength, muscle condition, and the physical capability that underpins independent living. The age-related deterioration of skeletal muscle is increasingly recognized as a priority for healthy aging, because the outcomes that matter most to older adults — rising from a chair, climbing stairs, staying steady and mobile — all depend on muscle that is both strong and well-maintained.

Yet most options available to brands address only part of the picture, or rest on thin evidence. The opportunity lies in an ingredient that supports muscle health on multiple fronts and is backed by rigorous data. HB05P was developed against exactly this need, with an evidence base spanning clinical muscle strength, supporting biomarkers, and a well-characterized mechanism of action.

Simultaneously, consumer and formulator interest is shifting from live probiotics toward postbiotics, which offer defined composition, room-temperature stability, and a simplified safety and regulatory narrative — attributes that matter for both shelf-stable finished products and global distribution.

The Ingredient: What HB05P Is

Because HB05P is heat-treated (pasteurized), it does not rely on the survival of living organisms through manufacture, shelf life, or transit. Potency is defined and verified by direct total-cell-count measurement, giving formulators a stable, quantifiable specification rather than a viability count that degrades over time.

A human milk-derived strain

Many commercial Akkermansia strains trace their origin to human feces. The HB05 strain, by contrast, was originally isolated from the milk of healthy Korean mothers. While the strain's functional benefits derive from its characterized biology and clinical data rather than its source, the origin story is one many brand and marketing teams find easier to communicate to consumers — a meaningful consideration for a category in which provenance shapes perception. It is a differentiating narrative asset that sits alongside, and does not replace, the regulatory and clinical substance described in this paper.

A First-in-Category Regulatory Position (U.S.)

For any brand, regulatory readiness is a gating factor. HB05P's standing is, to our knowledge, unmatched among Akkermansia ingredients in the U.S. market.

FDA New Dietary Ingredient (NDI) Notifications

HealthBiome has completed the FDA NDI notification process for HB05P at two intake levels — a low-dose and a high-dose notification — with FDA acknowledgement received for both. This provides partners a documented basis for lawful U.S. marketing of the ingredient as a dietary supplement, a position competitors in this strain category do not share.

Korean MFDS Approval (Individual Recognition)

In its home market, HB05P holds an MFDS individually-recognized functional ingredient approval for a muscle-strength benefit, articulated as: "may help to maintain muscle strength which can be decreased by aging." This dual-jurisdiction footing (U.S. NDI + Korean individual recognition) is a meaningful due-diligence advantage for global brands.

Mechanism: A Dual-Action Approach to Muscle Balance

Skeletal muscle is maintained by a balance between protein synthesis (anabolism) and protein breakdown (catabolism). Aging shifts this balance toward breakdown. Preclinical work indicates HB05P acts on both arms of this balance:

In preclinical models, these molecular changes translated into tangible benefits at the tissue level, including improved muscle condition and grip strength. This bidirectional mechanism — braking breakdown while supporting synthesis — distinguishes HB05P from single-pathway approaches and provides a coherent scientific story for both practitioner and consumer education.

Human Clinical Evidence

At the core of HB05P's muscle-health evidence are two randomized, double-blind, placebo-controlled human trials in older adults. Both measured muscle strength objectively and showed statistically significant between-group differences — the standard that separates a credible, substantiable ingredient from one supported only by within-group change.

5.1 High-dose trial (primary evidence)

All four co-primary lower-limb strength measures showed statistically significant between-group improvement favoring HB05P (p ≈ 0.007–0.008), with strength gains in the range of roughly 8.6–12.4%. Significant between-group effects were also seen in secondary measures including grip strength and lower-limb muscle power, alongside favorable movement in muscle biomarkers (myostatin, prealbumin; IGF-1).

This clinically demonstrated strength benefit is the human cornerstone of HB05P's muscle-health profile, and it is reinforced by a broader body of preclinical and mechanistic evidence (see Section 4). Together, these data describe an ingredient that supports muscle health on multiple levels, anchored by the rigorous, between-group human proof that brands need to substantiate confident structure/function claims.

5.2 Low-dose trial (supporting evidence)

An earlier 12-week RCT (N=100) at a lower intake (1.0×10¹⁰ cells/day) established initial proof of concept, with significant between-group improvement in lower-limb extensor strength. Results were published in a peer-reviewed nutrition journal. Together, the two trials describe a dose-responsive pattern: more consistent, broader efficacy at the higher dose.

An Emerging Application: Supporting Muscle Function During GLP-1 Weight Loss

The rapid adoption of GLP-1 receptor agonists (and dual GLP-1/GIP agonists) for weight management has created one of the most significant new conversations in nutrition. These medications produce substantial weight loss — but a portion of that loss is lean body mass, not only fat. Across the clinical literature, lean mass has commonly accounted for roughly one-quarter of total weight lost, with some analyses reporting higher fractions depending on the agent, dose, and population. This has prompted a wave of interest, across both pharma and nutrition, in strategies to protect muscle alongside GLP-1 therapy.

It is important to be precise about the science. The field is actively debating whether GLP-1-associated lean-mass change is maladaptive (a true threat to muscle health) or a largely adaptive response to a smaller body — and relative lean mass as a percentage of body weight is often preserved. What is less disputed is that the outcome older and at-risk users care about is muscle strength and function, and that maintaining it during and after weight loss is a shared goal of clinicians, brands, and consumers.

Where HB05P fits

HB05P is positioned as a muscle-supporting companion — an ingredient whose demonstrated benefit, the preservation of muscle strength and function, addresses the dimension of greatest concern during GLP-1 weight loss. Three features of HB05P's evidence base align with the GLP-1 companion concept:

• Comprehensive muscle support. HB05P's evidence base centers on clinically demonstrated muscle strength in older adults, reinforced by mechanistic and preclinical support for muscle condition — addressing muscle health as a whole, which is exactly the concern during GLP-1 weight loss.
• Anti-catabolic mechanism. The same pathways implicated in disuse- and atrophy-related muscle loss (myostatin, Atrogin-1, MuRF1) are those HB05P down-regulates in preclinical models — a mechanistic rationale for supporting muscle quality when intake and activity may be reduced.
• A complementary format. As a heat-treated postbiotic taken as a simple daily dose, HB05P fits naturally into the "GLP-1 companion" product formats — protein, fiber, and micronutrient blends — that brands are building for this consumer, without adding cold-chain or viability constraints.

Safety Profile

Across both human trials, HB05P was well tolerated, with no severe or product-related adverse events reported. As a heat-treated, non-viable preparation, it avoids the live-organism considerations that can complicate use in older or immune-compromised populations. A comprehensive GLP toxicology program (single-dose, repeated-dose, and genotoxicity studies) supports a wide margin of safety, with a high no-observed-adverse-effect level (NOAEL).

Why Formulate With HB05P